首页 | 官方网站   微博 | 高级检索  
     

缬沙坦加参麦注射液治疗充血性心力衰竭的临床观察
引用本文:张继明,侯召荣.缬沙坦加参麦注射液治疗充血性心力衰竭的临床观察[J].心脏杂志,2007,19(2):202-204.
作者姓名:张继明  侯召荣
作者单位:山东省医学科学院附属济宁市人民医院冠心病研究中心,山东,济南,250001
摘    要:目的观察缬沙坦(Valsartan)加参麦注射液(Shenmai Injection,SI)对充血性心力衰竭(CHF)心肌损害的疗效。方法采用随机分组的方法,分别用常规治疗(31例)和缬沙坦、SI加常规治疗(31例),并对CHF的各项实验室指标血浆肌钙蛋白T(cTnT)、心肌酶谱]进行观察。结果在CHF进程中,cTnT浓度随着心功能恶化呈进行性增高。应用缬沙坦加SI治疗2周后,患者左室收缩功能得到明显改善,未发现严重不良反应。结论血浆cTnT可作为CHF患者预后判断的一项重要生化指标。缬沙坦加SI是治疗CHF安全有效的药物。

关 键 词:缬沙坦    参麦注射液    心力衰竭  充血性    肌钙蛋白T    心功能
文章编号:1009-7236(2007)02-202-03
修稿时间:2006年2月17日

Clinical study on effect of Valsartan and Shenmai Injection in treating congestive heart failure
ZHANG Ji-ming,HOU Zhao-rong.Clinical study on effect of Valsartan and Shenmai Injection in treating congestive heart failure[J].Chinese Heart Journal,2007,19(2):202-204.
Authors:ZHANG Ji-ming  HOU Zhao-rong
Abstract:AIM To observe the therapeutic effect of Valsartan and Shenmai Injection(SI) in treating congestive heart failure(CHF).METHODS The changes in serum cardiac troponin T(cTnT),a specific marker reflecting myocardial injury,creatine kinase(CK) and creatine kinase isoenzyme(CK-MB) were simultaneously monitored in 62 chronic CHF patients.The subjects were randomized into two groups,the routine treatment group and the routine treatment Valsartan SI group,and the therapeutic effect of the two groups was compared.RESULTS The serum cTnT level progressively increased along with heart function deterioration.After treated with Valsartan and SI for 2 weeks,the hemodynamics of the CHF patients got stable and their heart function improved obviously.No serious adverse reaction was found in the therapeutic course.CONCLUSION The level of serum cTnT can be taken as a reliable biochemical parameter to predict the prognosis of CHF patients.Valsartan plus SI is safe and effective in treating CHF.
Keywords:valsartan  shenmai injective  congestive heart failure  troponin T  heart function
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《心脏杂志》浏览原始摘要信息
点击此处可从《心脏杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号